

Alon Altman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5432489/publications.pdf>

Version: 2024-02-01

66
papers

2,337
citations

304743

22
h-index

214800

47
g-index

66
all docs

66
docs citations

66
times ranked

2319
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendationsâ€™2019 update. International Journal of Gynecological Cancer, 2019, 29, 651-668.	2.5	452
2	Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERASÂ®) Society recommendations â€™ Part II. Gynecologic Oncology, 2016, 140, 323-332.	1.4	377
3	Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERASÂ®) Society recommendations â€™ Part I. Gynecologic Oncology, 2016, 140, 313-322.	1.4	360
4	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERASÂ®) Society Recommendations â€™ Part I: Preoperative and intraoperative management. European Journal of Surgical Oncology, 2020, 46, 2292-2310.	1.0	98
5	International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. American Journal of Obstetrics and Gynecology, 2019, 221, 237.e1-237.e11.	1.3	93
6	Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERASÂ®) Society Recommendations â€™ Part II: Postoperative management and special considerations. European Journal of Surgical Oncology, 2020, 46, 2311-2323.	1.0	79
7	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Modern Pathology, 2013, 26, 1255-1263.	5.5	52
8	Enhanced recovery after surgery: implementing a new standard of surgical care. Cmaj, 2019, 191, E469-E475.	2.0	52
9	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. Gynecologic Oncology, 2015, 139, 268-274.	1.4	50
10	Maternal Age-Related Rates of Gestational Trophoblastic Disease. Obstetrics and Gynecology, 2008, 112, 244-250.	2.4	46
11	Uterine Sarcoma and Aromatase Inhibitors: Tom Baker Cancer Centre Experience and Review of the Literature. International Journal of Gynecological Cancer, 2012, 22, 1006-1012.	2.5	39
12	Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center. International Journal of Gynecological Cancer, 2015, 25, 1616-1622.	2.5	38
13	The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples. PLoS Genetics, 2017, 13, e1006707.	3.5	36
14	Guidelines for vulvar and vaginal surgery: Enhanced Recovery After Surgery Society recommendations. American Journal of Obstetrics and Gynecology, 2020, 223, 475-485.	1.3	35
15	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecologic Oncology, 2016, 141, 148-154.	1.4	34
16	Impact of Nutrition on Enhanced Recovery After Surgery (ERAS) in Gynecologic Oncology. Nutrients, 2019, 11, 1088.	4.1	34
17	Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. Journal of Medical Genetics, 2018, 55, 571-577.	3.2	33
18	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 647-655.	2.5	28

#	ARTICLE	IF	CITATIONS
19	Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. <i>American Journal of Surgery</i> , 2019, 218, 537-550.	1.8	27
20	Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study. <i>Gynecologic Oncology</i> , 2020, 157, 234-244.	1.4	27
21	Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 397-404.	1.4	25
22	Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study. <i>Gynecologic Oncology</i> , 2017, 147, 257-261.	1.4	24
23	Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1748-1756.	2.5	24
24	Hormone Use After Nonserous Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2016, 127, 837-847.	2.4	22
25	Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 925-931.	2.5	21
26	The Effects of Anemia and Blood Transfusion on Patients With Stage III-IV Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1569-1576.	2.5	19
27	Examining the Effects of Time to Diagnosis, Income, Symptoms, and Incidental Detection on Overall Survival in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1637-1644.	2.5	18
28	New approaches to cancer care in a COVID-19 world. <i>Lancet Oncology</i> , The, 2020, 21, e339-e340.	10.7	18
29	Pfannenstiel Incision Closure: A Review of Current Skin Closure Techniques. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009, 31, 514-520.	0.7	17
30	No. 385-Indications for Pelvic Examination. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 1221-1234.	0.7	16
31	Hereditary Angioedema Managed with Low-Dose Danazol and C1 Esterase Inhibitor Concentrate: A Case Report. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2006, 28, 27-31.	0.7	15
32	Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples. <i>Gynecologic Oncology</i> , 2021, 161, 769-778.	1.4	15
33	Use of Aromatase Inhibitors as First-and Second-Line Medical Therapy in Patients With Endometrial Adenocarcinoma: A Retrospective Study. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 664-672.	0.7	14
34	The Canadian Gynaecologic Oncology Perioperative Management Survey: Baseline Practice Prior to Implementation of Enhanced Recovery After Surgery (ERAS) Society Guidelines. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, 1105-1109.e2.	0.7	12
35	Vacuum Assisted Wound Closures in Gynaecologic Surgery. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2011, 33, 1031-1037.	0.7	11
36	Luteinized Thecomas (â€œThecomatosisâ€œ) with Sclerosing Peritonitis (LTSP): Report of 2 Cases and Review of an Enigmatic Syndrome Associated with a Peritoneal Proliferation of Specialized (vimentin+/keratin+/CD34+) Submesothelial Fibroblasts. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, 41-50.	0.7	11

#	ARTICLE	IF	CITATIONS
37	Optimal Debulking Targets in Women With Advanced Stage Ovarian Cancer: A Retrospective Study of Immediate Versus Interval Debulking Surgery. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 558-566.	0.7	9
38	Time to Surgery and the Risk of Cancer Progression in Patients With Gynaecologic Cancers of the Lower Genital Tract. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2015, 37, 338-344.	0.7	6
39	Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IA1/IA2 cervical cancer: 4C (Canadian Cervical Cancer) Tj ETQq1 1 0.784314 rgB.4/Overlook 10 Tf 50		
40	Postoperative Infection in the Setting of Massive Intraoperative Blood Loss. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, 1110-1113.	0.7	5
41	A molecular assessment of homing in the tidepool sculpin. <i>Journal of Fish Biology</i> , 2003, 62, 623-640.	1.6	4
42	Tubal Teratoma Causing Anti-NMDAR Encephalitis. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014, 36, 1093-1096.	0.7	4
43	Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo. <i>Translational Oncology</i> , 2021, 14, 101203.	3.7	4
44	Spontaneous Rupture of an Unscarred Uterus Diagnosed Postpartum: A Case Report. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2015, 37, 1021-1024.	0.7	3
45	Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5515-5515.	1.6	3
46	Vulvar postoperative care, gestalt or evidence based medicine? A comprehensive systematic review. <i>Gynecologic Oncology</i> , 2017, 145, 386-392.	1.4	2
47	Diagnostic and referral intervals for Manitoba women with epithelial ovarian cancer - the Manitoba Ovarian Cancer Outcomes (MOCO) study group: a retrospective cross-sectional study. <i>CMAJ Open</i> , 2017, 5, E116-E122.	2.4	2
48	Low-Risk Gestational Trophoblastic Neoplasia in Manitoba: Experience With Alternating Methotrexate and Dactinomycin. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1448-1452.	2.5	2
49	Uterine Inversion as a Result of a Large Prolapsed Carcinosarcoma of the Uterus. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 1181-1184.	0.7	2
50	The Risk of Postoperative Infectious Complications Following Massive Intraoperative Blood Loss During Gynaecologic Laparotomy: Retrospective Cohort Study. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 19-25.	0.7	2
51	The Canadian Gynecologic Oncology Peri-operative Management Survey: re-examining Enhanced Recovery After Surgery (ERAS) recommendations. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1039-1044.	2.5	2
52	Paraneoplastic myositis secondary to poorly differentiated serous carcinoma of ovarian/tubal origin. <i>Gynecologic Oncology Reports</i> , 2017, 20, 112-114.	0.6	1
53	Examining the Selection Criteria of Neoadjuvant Chemotherapy Patients. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 595-603.	0.7	1
54	Rate of Appendiceal Metastasis with Non-Serous Epithelial Ovarian Cancer in Manitoba. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 180-185.	0.7	1

#	ARTICLE	IF	CITATIONS
55	No 385 - Indications de l'examen pelvien. Journal of Obstetrics and Gynaecology Canada, 2019, 41, 1235-1250.	0.7	1
56	Guidelines for Perioperative Care in Gynecologic/Oncology: Enhanced Recovery After Surgery (ERAS) Society Recommendations 2019 Update. Obstetrical and Gynecological Survey, 2019, 74, 408-409.	0.4	1
57	Canadian Enhanced Recovery After Surgery (ERAS) Cesarean Delivery Perioperative Management Survey. Journal of Obstetrics and Gynaecology Canada, 2021, , .	0.7	1
58	Extra-uterine endometrial stromal sarcoma of the left adnexa and distal ureter: A case report. Gynecologic Oncology Reports, 2021, 36, 100702.	0.6	1
59	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current Oncology, 2022, 29, 4354-4369.	2.2	1
60	The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer. Cancers, 2022, 14, 3318.	3.7	1
61	Response to Multi-Line Chemotherapy in Non-Serous Epithelial Ovarian Cancer. Journal of Obstetrics and Gynaecology Canada, 2020, 42, 1217-1222.	0.7	0
62	Perioperative incidence of venous thromboembolism in patients with ovarian cancer using 4 different data collection methods: a Manitoba Ovarian Cancer Outcomes (MOCO) group study. Journal of Obstetrics and Gynaecology Canada, 2021, , .	0.7	0
63	Gynecologic/Oncology Surgery. , 2020, , 443-456.		0
64	Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman Study™. Current Oncology, 2022, 29, 3318-3340.	2.2	0
65	A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma. International Journal of Gynecological Cancer, 0, , ijgc-2021-003210.	2.5	0
66	Venous thromboembolic prophylaxis. , 2022, , 161-175.		0